BATON ROUGE, La., Oct. 2, 2024 /PRNewswire/ -- Ambetter from Louisiana Healthcare Connections, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer a variety of affordable health insurance plans to Louisianans in 22 parishes for plan year 2025. Open enrollment for the Health Insurance Marketplace in Louisiana runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
"We are honored to bring our affordable healthcare solutions to even more Louisianans in the year to come," said Jamie Schlottman, Louisiana Healthcare Connections plan president and CEO. "With Ambetter from Louisiana Healthcare Connections plans, members can rely on accessible and convenient care that provides the coverage and support they need."
Ambetter from Louisiana Healthcare Connections offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is the full list of parishes in which Ambetter from Louisiana Healthcare Connections will be offered in 2025:
Louisiana residents interested in learning more about Ambetter from Louisiana Healthcare Connections or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/la.
About Ambetter from Louisiana Healthcare Connections
Ambetter from Louisiana Healthcare Connections serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter from Louisiana Healthcare Connections is underwritten by Ambetter Health of Louisiana, Inc., which is a Qualified Health Plan issuer in Louisiana. For more information, visit ambetterhealth.com/en/la. This is a solicitation for insurance. For information on your right to receive an Ambetter from Louisiana Healthcare Connections plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$29.04 |
Daily Change: | 0.66 2.33 |
Daily Volume: | 7,803,803 |
Market Cap: | US$14.260B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load